No long entry here, I'll just give you the Feds' own summary so you can read the whole thing later, at your leisure (I added formatting to parse out the parts):
We also reverse the district court’s decision that Myriad’s method claim to screening potential cancer therapeutics via changes in cell growth rates of transformed cells is directed to a patent-ineligible scientific principle.
We affirm the court’s decision, however, that Myriad’s method claims directed to “comparing” or “analyzing” DNA sequences are patent ineligible; such claims include no transformative steps and cover only patent-ineligible abstract, mental steps.
… … … … … … … … … … … … … … … … … … …
… … … … … … … … « — » … … … … … … … … …
… … … … … … … … … … … … … … … … … … …